January 28, 2019

Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy

January 8, 2019

UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

January 3, 2019

UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer

December 4, 2018

Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

November 28, 2018

Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities

October 15, 2018

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 10, 2018

Allogene Therapeutics Announces Pricing of Initial Public Offering

October 2, 2018

FierceBiotech names Kronos Bio as one of its “Fierce 15” Biotech Companies of 2018

September 27, 2018

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

September 14, 2018

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

September 6, 2018

Allogene Therapeutics Completes a $120 Million Private Financing

August 28, 2018

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality

August 14, 2018

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

July 10, 2018

Allogene Therapeutics Announces Scientific Advisory Board

June 18, 2018

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

June 5, 2018

UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance

June 4, 2018

Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer

May 30, 2018

Allogene Therapeutics Announces Board of Directors

May 23, 2018

Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing

May 21, 2018

UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

May 16, 2018

Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breakter at the International Investigative Dermatology Congress

May 15, 2018

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

April 3, 2018

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

March 12, 2018

Sienna Biopharmaceuticals announces First Patient Dosed in Proof-Of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis

February 22, 2018

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer